Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,156 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Structural Intervention Clear all
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Assessment of Spinal Cord Structural Plasticity Using DTI in SCI Patients

NCT03069222
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Standard Rehabilitative Treatment
Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 7, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The STRENGTHEN Study

NCT06267521
View directory record Official record
Conditions
Cognitive Flexibility, Emotional Regulation
Interventions
Healthy Minds Program, Sham Meditation Didactic Material, Sham Stimulation in Lab, Stimulation in Lab, MRI Scanner
Other · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Phase 3 Interventional

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

NCT06945315
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
RALP (Robotic-assisted radical prostatectomy), SAFE (Saline assisted fascial engorgement)
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 7, 2026, 5:07 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

NCT05828082
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Phase 1 Interventional

Studying TAK-243 in Patients With Advanced Cancer

NCT06223542
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, UAE Inhibitor TAK-243
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Completed Not applicable Interventional

The IGNITE for Kids Study on Concentrated Investment in Black Neighborhoods and Child Health and Well-Being

NCT05760001
View directory record Official record
Conditions
Financial Stress, Economic Problems, Environmental Exposure, Health Behavior, Health, Subjective, Mental Health Wellness
Interventions
Assigned Interventions
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
3 Years to 19 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module

NCT03530449
View directory record Official record
Conditions
Retinal Vascular, Normal Eyes
Interventions
OCT Angiography, Color Fundus Photography, Optical Coherence Tomography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 7, 2026, 5:07 AM EDT
Not listed Phase 1 Interventional

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

NCT03278925
View directory record Official record
Conditions
Cirrhosis
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Questionnaire Administration, Ultrasound
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 7, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating a Structural and Behavioral HIV Risk Reduction Program for Black Men

NCT01694121
View directory record Official record
Conditions
HIV
Interventions
MEN Count, Comparison
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 7, 2026, 5:07 AM EDT
Suspended Phase 1 Interventional

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

NCT06922604
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Glofitamab, Lumbar Puncture, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

NCT02631733
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Veliparib
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 7, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 7, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic

NCT04459455
View directory record Official record
Conditions
Anxiety
Interventions
Contain COVID Anxiety SSI, Remain COVID Free SSI
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

NCT06769126
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
148
States / cities
Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

NCT06860815
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions
Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
Procedure · Biological · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform

NCT06573476
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
PRC supported text + AI driven CSDH-enhanced text, AI driven CSDH-enhanced text only, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Randomized Evaluation of Voucher Interventions for Value and Effectiveness (REVIVE) in Philippines

NCT07640594
View directory record Official record
Conditions
Food Insecurity, Undernutrition, Diet Quality, Nutrition Knowledge
Interventions
Food Voucher + SBCC (PhP 3,000), Food Voucher + SBCC (PhP 5,000), Food Voucher + SBCC (PhP 8,000)
Behavioral
Lead sponsor
International Food Policy Research Institute
Other
Eligibility
0 Months to 99 Years
Enrollment
5,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

NCT01149083
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Veliparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 7, 2026, 5:07 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Completed No phase listed Observational

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

NCT01344837
View directory record Official record
Conditions
Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Medical Chart Review, Microarray Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting
Other · Genetic
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 7, 2026, 5:07 AM EDT
Enrolling by invitation Not applicable Interventional

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT06494631
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Xeltis Hemodialysis Access (aXess) graft
Device
Lead sponsor
Xeltis
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Phoenix, Arizona • Tuscon, Arizona • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
323
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Noninvasive Therapy for Tinnitus

NCT07071480
View directory record Official record
Conditions
Tinnitus, Tinnitus, Subjective
Interventions
Cold pack-delivered mild therapeutic hypothermia, Sham device
Device
Lead sponsor
Restorear Devices LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 7, 2026, 5:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

NCT04939597
View directory record Official record
Conditions
Central Nervous System Carcinoma
Interventions
Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
137
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 7, 2026, 5:07 AM EDT